Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-07-19
2011-07-19
Gussow, Anne M. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387300, C530S387700, C530S388150, C424S130100, C424S133100, C424S142100
Reexamination Certificate
active
07982013
ABSTRACT:
Novel anti-cancer agents, including, but not limited to, antibodies, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided.
REFERENCES:
patent: 6127526 (2000-10-01), Blank
patent: 6252050 (2001-06-01), Ashkenazi et al.
patent: 6433155 (2002-08-01), Umansky et al.
patent: 6660843 (2003-12-01), Feige et al.
patent: 7091321 (2006-08-01), Gillies et al.
patent: 7361336 (2008-04-01), Bergstein
patent: 7381408 (2008-06-01), Mezo et al.
patent: 7404956 (2008-07-01), Peters et al.
patent: 7442778 (2008-10-01), Gegg et al.
patent: 7507406 (2009-03-01), Gillies et al.
patent: 7659116 (2010-02-01), Buehring et al.
patent: 7682607 (2010-03-01), Rhee et al.
patent: 7713526 (2010-05-01), Rhee et al.
patent: 7723477 (2010-05-01), Gurney et al.
patent: 2002/0137129 (2002-09-01), Barnes et al.
patent: 2002/0169300 (2002-11-01), Waterman et al.
patent: 2002/0187502 (2002-12-01), Waterman et al.
patent: 2003/0044409 (2003-03-01), Carson et al.
patent: 2003/0162709 (2003-08-01), Rossi et al.
patent: 2003/0165500 (2003-09-01), Rhee et al.
patent: 2003/0229023 (2003-12-01), Oliner et al.
patent: 2004/0105862 (2004-06-01), Pan et al.
patent: 2004/0171559 (2004-09-01), Weissman et al.
patent: 2004/0203003 (2004-10-01), Rhee et al.
patent: 2004/0247593 (2004-12-01), He et al.
patent: 2005/0272063 (2005-12-01), Nakamura et al.
patent: 2005/0288864 (2005-12-01), Cattaneo et al.
patent: 2006/0019256 (2006-01-01), Clarke et al.
patent: 2006/0019320 (2006-01-01), Civenni et al.
patent: 2007/0116701 (2007-05-01), Gurney et al.
patent: 2007/0237770 (2007-10-01), Lai et al.
patent: 2008/0044423 (2008-02-01), Cochrane et al.
patent: 2008/0075714 (2008-03-01), Lee et al.
patent: 2008/0118432 (2008-05-01), Bergstein et al.
patent: 2008/0194457 (2008-08-01), Wands et al.
patent: 2008/0299136 (2008-12-01), Ernst et al.
patent: 2009/0074777 (2009-03-01), Wands et al.
patent: 2009/0130113 (2009-05-01), Kneissel et al.
patent: 2009/0163407 (2009-06-01), Bafico et al.
patent: 2009/0186010 (2009-07-01), Li et al.
patent: 2009/0234104 (2009-09-01), Gegg et al.
patent: 2009/0304695 (2009-12-01), He et al.
patent: 1 576 119 (2005-09-01), None
patent: 1 805 221 (2006-04-01), None
patent: 1 805 519 (2007-07-01), None
patent: WO 01/26643 (2001-04-01), None
patent: WO 02/088081 (2002-11-01), None
patent: WO 02/092635 (2002-11-01), None
patent: WO 03/004045 (2003-01-01), None
patent: WO 2004/020668 (2004-03-01), None
patent: WO 2004/032838 (2004-04-01), None
patent: WO 2004/042028 (2004-05-01), None
patent: WO 2004/053069 (2004-06-01), None
patent: WO 2004/101739 (2004-11-01), None
patent: WO 2005/001025 (2005-01-01), None
patent: WO 2005/005601 (2005-01-01), None
patent: WO 2006/034328 (2006-03-01), None
patent: WO 2006/036173 (2006-04-01), None
patent: WO 2006/036175 (2006-04-01), None
patent: WO 2006/055635 (2006-05-01), None
patent: WO 2006/056340 (2006-06-01), None
patent: WO 2007/053577 (2007-05-01), None
patent: WO 2007/096149 (2007-08-01), None
patent: WO 2007/134876 (2007-11-01), None
patent: WO 2007/142711 (2007-12-01), None
patent: WO 2007/148417 (2007-12-01), None
patent: WO 2008/031009 (2008-03-01), None
patent: WO 2008/057459 (2008-05-01), None
patent: WO 2008/061020 (2008-05-01), None
patent: WO 2009/118300 (2009-10-01), None
patent: WO 2010/031979 (2010-03-01), None
patent: WO 2010/038756 (2010-08-01), None
Burgess, Shaheen, Ravera, Jaye, Donohue, and Winkles. Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor binding activities by site directed mutagenesis of a single lysine residue. Journal of Cell Biology, 1990. vol. 111, pp. 2129-2138.
Lazar, Watanabe, Dalton, and Sporn. Transforming growth factor alpha: mutation of aspartic acid 47 and leucine 48 results in different biological activities. Molecular and Cellular Biology, 1988. vol. 8, pp. 1247-1252.
Rudikoff, Giusti, Cook, and Scharff. Single amino acid substitution altering antigen-binding specificity. Proceedings of the National Academy of Sciences, 1982. vol. 79, pp. 1979-1982.
Mac Callum, Martin, and Thornton. Antibody-antigen interactions: contact analysis and binding site topography. Journal of Molecular Biology, 1996. vol. 262, pp. 732-745.
De Pascalis, Iwahashi, Tamura, Padlan, Gonzales, Santos, Giuliano, Schuck, Schlom, and Kashmiri. Grafting of abbreviated complementarity determining regions containing specificity determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody. Journal of Immunology, 2002. vol. 169, pp. 3076-3084.
Casset, Roux, Mouchet, Bes, Chardes, Granier, Mani, Pugniere, Laune, Pau, Kaczorek, Lahana, and Rees. A peptide mimetic of an anti-CD4 monoclonal antibody by rational design. Biochemical and Biophysical Research Communications, 2003. vol. 307, pp. 198-205.
Vajdos, Adams, Breece, Presta, De Vos, and Sidhu. Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis. Journal of Molecular Biology, 2002. vol. 320, pp. 415-428.
Holm, Jafari, and Sundstrom. Functional mapping and single chain construction of the anti-cytokeratin 8 monoclonal antibody TS1. Molecular Immunology, 2007. vol. 44, pp. 1075-1084.
Chen, Wiesmann, Fuh, Li, Christinger, Mc Kay, De Vos, and Lowman. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity matured Fab in complex with antigen. Journal of Molecular Biology, 1999. vol. 293, pp. 865-881.
Wu, Nie, Huse, and Watkins. Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues. Journal of Molecular Biology, 1999. vol. 294, pp. 151-162.
Ayyanan, A., et al., “Increased Wnt signaling triggers oncogenic conversion of human breast epithelial cells by a Notch-dependent mechanism,”PNAS, 103:3799-3804, the National Academy of Sciences, U.S.A. (2006).
Bafico, A., et al., “Interaction of Frizzled Related Protein (FRP) with Wnt Ligands and the Frizzled Receptor Suggests Alternative Mechanisms for FRP Inhibition of Wnt Signaling,”J. Biol. Chem., 274:16180-16187, The American Society for Biochemistry and Molecular Biology, Inc. U.S.A. (1999).
Barker, N., and Clevers, H., “Mining the Wnt pathway for cancer therapeutics,”Nature Reviews/Drug Discovery5:997-1014, Nature Publishing Group, U.S.A. (2006).
Battula, V.L., et al., “Prospective isolation and characterization of mesenchymal stem cells from human placenta using a frizzled-9-specific monoclonal antibody,”Differentiation, 76:326-336, International Society of Differentiation, U.S.A. (2008).
Benhamouche, S., et al., “Apc Tumor Suppressor Gene Is the “Zonation-Keeper” of Mouse Liver,”DevelopmentalCell, 10:759-770, Elsevier Inc., The Netherlands (2006).
Bhanot, P., et al., “A new member of the frizzled family from Drosophila functions as a Wingless receptor,”Nature, 382:225-230, Nature Publishing Group, U.S.A. (1996).
Bienz, M., “β-Catenin: A Pivot between Cell Adhesion and Wnt Signalling,”Current Biology, 15:R64-R67, Cell Press, U.S.A. (2004).
Booy, E.P., et al., “Monoclonal and bispecific antibodies as novel therapeutics,”Arch. Immunol. Ther. Exp., 54:85-101, Birkhäuser Publications, Switzerland (2006).
Brennan, K.R., and Brown, A.M.C., “Wnt Proteins in Mammary Development and Cancer,”J. Mammary Gland Biol., Neoplasia, 9:119-131, Kluwer Academic/Plenum Publishers, U.S.A. (2004).
Burgess, W.H., et al., “Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue,”J. Cell Bio.,
Axelrod Fumiko Takada
Gurney Austin L.
Hoey Timothy Charles
Mitra Satyajit Sujit Kumar
Sato Aaron Ken
Gussow Anne M.
OncoMed Pharmaceuticals, Inc.
Sterne Kessler Goldstein & Fox P.L.L.C.
LandOfFree
Frizzled-binding agents and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Frizzled-binding agents and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Frizzled-binding agents and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2699205